Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryMay 02, 2019 Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results View HTML Toggle SummaryApr 26, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryApr 26, 2019 Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results View HTML Toggle SummaryApr 23, 2019 Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting View HTML Toggle SummaryApr 22, 2019 U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab View HTML Toggle SummaryApr 12, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryApr 08, 2019 Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer View HTML Toggle SummaryApr 02, 2019 Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference View HTML Toggle SummaryMar 05, 2019 Alder BioPharmaceuticals® to Present at the Cowen and Company 39th Annual Health Care Conference View HTML Toggle SummaryMar 04, 2019 Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares View HTML Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
